title: Sodium valproate, a histone deacetylase inhibitor, decreases the secretion of soluble Fas by human osteosarcoma cells and increases their sensitivity to Fas-mediated cell death.
abstract: OBJECTIVE
  Effects of valproic acid (VPA), a histone deacetylase inhibitor, on the susceptibility to cell death induced by agonistic anti-Fas antibody were examined using four human osteosarcoma cell lines.
  
  
  METHODS
  Cell growth, secretion of soluble Fas, expression of cell-surface Fas, and sensitivity to Fas-mediated cell death were examined using cell proliferation assay, flow cytometry, enzyme-linked immunosorbent assay, and agonistic anti-Fas antibody, respectively.
  
  
  RESULTS
  VPA suppressed the growth of all the four osteosarcoma cell lines and the secretion of soluble Fas from these cells. VPA showed no or slight suppressive effect on the expression of cell-surface Fas in the four osteosarcoma cell lines, but increased the sensitivity of three of four osteosarcoma cell lines to Fas-mediated cell death.
  
  
  CONCLUSIONS
  VPA enhances the susceptibility of human osteosarcoma cells to Fas-ligand-induced cell death by decreasing the secretion of soluble Fas and increasing the sensitivity to Fas-mediated cell death.
authors.affiliation: Department of Pathology, Hyogo College of Medicine, 1-1 Mukogawa-cho, Nishinomiya, Hyogo, 663-8501, Japan. yamanegi@hyo-med.ac.jp
authors.forename: Koji
authors.initials: K
authors.lastname: Yamanegi
authors.forename: Junko
authors.initials: J
authors.lastname: Yamane
authors.forename: Masaki
authors.initials: M
authors.lastname: Hata
authors.forename: Hideki
authors.initials: H
authors.lastname: Ohyama
authors.forename: Naoko
authors.initials: N
authors.lastname: Yamada
authors.forename: Nahoko
authors.initials: N
authors.lastname: Kato-Kogoe
authors.forename: Hiroyuki
authors.initials: H
authors.lastname: Futani
authors.forename: Keiji
authors.initials: K
authors.lastname: Nakasho
authors.forename: Haruki
authors.initials: H
authors.lastname: Okamura
authors.forename: Nobuyuki
authors.initials: N
authors.lastname: Terada
mesh_terms: D000906:Antibodies / Q000494:pharmacology*; D001859:Bone Neoplasms / Q000378:metabolism* / Q000473:pathology; D016923:Cell Death / Q000187:drug effects; D049109:Cell Proliferation / Q000187:drug effects; D015536:Down-Regulation / Q000187:drug effects; D004353:Drug Evaluation, Preclinical; D004357:Drug Synergism; D004791:Enzyme Inhibitors / Q000494:pharmacology; D006655:Histone Deacetylases / Q000494:pharmacology; D006657:Histones / Q000378:metabolism; D006801:Humans; D012516:Osteosarcoma / Q000378:metabolism* / Q000473:pathology; D012995:Solubility; D014407:Tumor Cells, Cultured; D014635:Valproic Acid / Q000494:pharmacology*; D019014:fas Receptor / Q000276:immunology / Q000378:metabolism*
chemical_list: D000906:Antibodies; D004791:Enzyme Inhibitors; D006657:Histones; D019014:fas Receptor; D014635:Valproic Acid; D006655:Histone Deacetylases